Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
Want to see COYA full AI Analyst Report?
Top Page
Coya Therapeutics, Inc.
(NASDAQ:COYA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$4.00
▼(-16.32% Downside)
Action:ReiteratedDate:05/12/26
The score is held down primarily by ongoing losses and persistent cash burn, alongside a weak technical trend (below major moving averages with negative MACD). Offsetting factors include a low-leverage balance sheet and constructive corporate milestones (Fast Track/IND progress and new financing), but valuation remains constrained by unprofitability.
Positive Factors
Regulatory Momentum
Fast Track status provides more frequent FDA interactions, potential rolling review and eligibility for expedited programs. These structural regulatory advantages can shorten development and review timelines, increase approval probability, and improve partner/financing optionality over the medium term.
Negative Factors
Persistent Cash Burn
Consistent negative operating and free cash flow (~-$10M/year) means the company will need additional funding until it achieves sustainable revenues or partner deals. That recurring burn elevates dilution and financing risk, and makes long-term program execution contingent on successful capital raises or collaborations.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Momentum
Fast Track status provides more frequent FDA interactions, potential rolling review and eligibility for expedited programs. These structural regulatory advantages can shorten development and review timelines, increase approval probability, and improve partner/financing optionality over the medium term.
Read all positive factors
Coya Therapeutics, Inc. (COYA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$96.41M
Dividend YieldN/A
Average Volume (3M)266.35K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue Growth123.57%
EPS Growth-22.26%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.27
Shares Outstanding23,457,184
10 Day Avg. Volume216,274
30 Day Avg. Volume266,345
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.26
Price to Sales (P/S)12.21
P/FCF Ratio-9.04
Enterprise Value/Market Cap0.23
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit2.77
Enterprise Value/Ebitda-1.08
Forecast
1Y Price Target
$16.25Price Target Upside239.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$1.92M
Coya Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as T...
How the Company Makes Money
null...
Coya Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
63
Positive
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.95M | 3.55M | 6.00M | 0.00 | 0.00 |
| Gross Profit | 7.92M | -8.31M | 500.68K | -4.41M | 0.00 |
| EBITDA | -20.24M | -17.20M | -7.33M | -9.26M | -4.85M |
| Net Income | -21.23M | -14.88M | -7.99M | -12.24M | -4.89M |
Balance Sheet | |||||
| Total Assets | 49.95M | 44.35M | 41.26M | 8.40M | 4.79M |
| Cash, Cash Equivalents and Short-Term Investments | 46.82M | 38.34M | 32.63M | 5.93M | 4.34M |
| Total Debt | 0.00 | 0.00 | 0.00 | 12.97M | 0.00 |
| Total Liabilities | 6.92M | 4.77M | 5.63M | 16.79M | 1.15M |
| Stockholders Equity | 43.03M | 39.58M | 35.64M | -8.39M | 3.64M |
Cash Flow | |||||
| Free Cash Flow | -10.74M | -10.29M | -11.19M | -7.24M | -4.04M |
| Operating Cash Flow | -10.74M | -10.29M | -11.19M | -7.24M | -3.90M |
| Investing Cash Flow | -1.16M | -25.00K | -543.19K | -525.00K | -136.80K |
| Financing Cash Flow | 20.39M | 16.03M | 38.43M | 9.36M | -340.58K |
Coya Therapeutics, Inc. Technical Analysis
Neutral
4.78
Price Trends
4.54
Positive
4.96
Negative
5.55
Negative
Market Momentum
0.01
Negative
60.58
Neutral
90.76
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COYA, the sentiment is Neutral. The current price of 4.78 is above the 20-day moving average (MA) of 4.21, above the 50-day MA of 4.54, and below the 200-day MA of 5.55, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 60.58 is Neutral, neither overbought nor oversold. The STOCH value of 90.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for COYA.
Coya Therapeutics, Inc. Risk Analysis
Coya Therapeutics, Inc. disclosed 80 risk factors in its most recent earnings report. Coya Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Coya Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $148.20M | 1.04 | 22.53% | ― | 117.62% | ― | |
53 Neutral | $227.42M | -1.25 | -30.02% | ― | ― | 15.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $525.26M | -12.22 | -60.73% | ― | -78.29% | 54.16% | |
46 Neutral | $119.63M | 54.17 | -353.36% | ― | -69.99% | 51.48% | |
45 Neutral | $96.41M | -4.57 | -64.33% | ― | 123.57% | -22.26% | |
44 Neutral | $78.73M | -2.18 | -159.43% | ― | ― | 27.86% |
* Healthcare Sector Average
COYA
Coya Therapeutics, Inc.
4.18
-1.96
-31.92%
INO
Inovio Pharmaceuticals
1.43
-0.51
-26.29%
SPRO
Spero Therapeutics
2.55
1.94
318.03%
ANVS
Annovis Bio
2.39
0.84
54.19%
NKTX
Nkarta
3.18
1.16
57.43%
STTK
Shattuck Labs
7.02
6.03
609.09%
Coya Therapeutics, Inc. Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Coya Therapeutics Updates Q1 Results, COYA 302 Progress
Positive
May 12, 2026
On May 12, 2026, Coya Therapeutics reported first-quarter 2026 results and a corporate update, highlighting U.S. FDA Fast Track Designation granted on March 11, 2026 for its ALS candidate COYA 302 and FDA acceptance of an IND for COYA 302 in front...
Business Operations and StrategyExecutive/Board Changes
Coya Therapeutics Announces Leadership Changes and New Director
Neutral
Apr 2, 2026
Coya Therapeutics, Inc. is a Houston-based, clinical-stage biotechnology company focused on developing proprietary treatments that leverage regulatory T cells to address systemic inflammation and neuroinflammation. Its pipeline includes Treg-enhan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.